Floatz logo

Itacitinib

Hodgkin Disease

Washington University School of MedicineSmall moleculePhase 2Dormant
CCC
51/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
36/ 100
Competitive Position
89/ 100

Competitive context

150 Active assets in the Hodgkin Disease cohort.

Asset / SponsorPhaseRating
FILGRASTIM
Fred Hutchinson Cancer Center
Phase 3BBB
CYCLOSPORIN A
City of Hope Medical Center
Phase 3BBB
Carboplatin
St. Petersburg State Pavlov Medical University
Phase 2BBB
Cytosin-Arabinosid
Therapeutic Advances in Childhood Leukemia Consortium
Phase 3BBB
Everolimus
OHSU Knight Cancer Institute
Phase 2BBB

View all 50 →

Same molecule, other indications

Itacitinib is also rated in:

cancerDormant
CCC
Indicative ·
51 / 100
View asset →
acute myeloid leukemiaDormant
CCC
Indicative ·
51 / 100
View asset →
myeloproliferative neoplasmDormant
CCC
Indicative ·
51 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →